Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Liabilities and Shareholders Equity (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Liabilities and Shareholders Equity data on record, last reported at $126.4 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 36.03% year-over-year to $126.4 million; the TTM value through Sep 2025 reached $584.3 million, up 144.04%, while the annual FY2024 figure was $170.5 million, 190.26% up from the prior year.
  • Liabilities and Shareholders Equity reached $126.4 million in Q3 2025 per CAPR's latest filing, down from $133.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $170.5 million in Q4 2024 and bottomed at $37.2 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $71.3 million, with a median of $53.9 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 31.11% in 2023, then soared 248.95% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $41.3 million in 2021, then grew by 21.21% to $50.1 million in 2022, then rose by 17.25% to $58.7 million in 2023, then soared by 190.26% to $170.5 million in 2024, then dropped by 25.83% to $126.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $126.4 million in Q3 2025, $133.6 million in Q2 2025, and $153.8 million in Q1 2025.